CN101299933B - 包含二十二碳六烯酸和叶黄素的婴儿配方 - Google Patents
包含二十二碳六烯酸和叶黄素的婴儿配方 Download PDFInfo
- Publication number
- CN101299933B CN101299933B CN2006800396657A CN200680039665A CN101299933B CN 101299933 B CN101299933 B CN 101299933B CN 2006800396657 A CN2006800396657 A CN 2006800396657A CN 200680039665 A CN200680039665 A CN 200680039665A CN 101299933 B CN101299933 B CN 101299933B
- Authority
- CN
- China
- Prior art keywords
- lutein
- product
- infant formula
- dha
- baby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 title claims abstract description 150
- 229960005375 lutein Drugs 0.000 title claims abstract description 145
- 235000012680 lutein Nutrition 0.000 title claims abstract description 145
- 239000001656 lutein Substances 0.000 title claims abstract description 145
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 title claims abstract description 145
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title claims abstract description 145
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 title claims abstract description 145
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 127
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title abstract description 51
- 229940090949 docosahexaenoic acid Drugs 0.000 title abstract 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 title abstract 3
- 229940088594 vitamin Drugs 0.000 claims abstract description 25
- 229930003231 vitamin Natural products 0.000 claims abstract description 25
- 235000013343 vitamin Nutrition 0.000 claims abstract description 25
- 239000011782 vitamin Substances 0.000 claims abstract description 25
- 238000011161 development Methods 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 20
- 239000011707 mineral Substances 0.000 claims abstract description 20
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 123
- 230000000007 visual effect Effects 0.000 claims description 24
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 21
- 210000001525 retina Anatomy 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 208000017442 Retinal disease Diseases 0.000 claims description 8
- 206010038923 Retinopathy Diseases 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 2
- 241000736851 Tagetes Species 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 36
- 235000018102 proteins Nutrition 0.000 abstract description 18
- 235000019197 fats Nutrition 0.000 abstract description 14
- 235000014633 carbohydrates Nutrition 0.000 abstract description 13
- 235000010755 mineral Nutrition 0.000 abstract description 11
- 230000004438 eyesight Effects 0.000 abstract description 10
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000004262 retinal health Effects 0.000 abstract 1
- 239000002002 slurry Substances 0.000 description 35
- 206010001497 Agitation Diseases 0.000 description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 32
- 238000013019 agitation Methods 0.000 description 29
- 239000000463 material Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 235000020256 human milk Nutrition 0.000 description 23
- 210000004251 human milk Anatomy 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 230000018109 developmental process Effects 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 15
- 235000008504 concentrate Nutrition 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 235000010323 ascorbic acid Nutrition 0.000 description 14
- 239000011668 ascorbic acid Substances 0.000 description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 14
- 235000016709 nutrition Nutrition 0.000 description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 10
- 230000035611 feeding Effects 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 230000035764 nutrition Effects 0.000 description 10
- 239000001508 potassium citrate Substances 0.000 description 10
- 229960002635 potassium citrate Drugs 0.000 description 10
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 10
- 235000011082 potassium citrates Nutrition 0.000 description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 9
- 235000013339 cereals Nutrition 0.000 description 9
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960001231 choline Drugs 0.000 description 8
- 239000011790 ferrous sulphate Substances 0.000 description 8
- 235000003891 ferrous sulphate Nutrition 0.000 description 8
- 229960000367 inositol Drugs 0.000 description 8
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 8
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 229960003080 taurine Drugs 0.000 description 8
- 230000004304 visual acuity Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 7
- 229930003471 Vitamin B2 Natural products 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 7
- 239000003240 coconut oil Substances 0.000 description 7
- 235000019864 coconut oil Nutrition 0.000 description 7
- 229960000304 folic acid Drugs 0.000 description 7
- 235000019152 folic acid Nutrition 0.000 description 7
- 239000011724 folic acid Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- 235000001968 nicotinic acid Nutrition 0.000 description 7
- 239000011664 nicotinic acid Substances 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229960002477 riboflavin Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000003549 soybean oil Substances 0.000 description 7
- 235000012424 soybean oil Nutrition 0.000 description 7
- 239000011573 trace mineral Substances 0.000 description 7
- 235000019164 vitamin B2 Nutrition 0.000 description 7
- 239000011716 vitamin B2 Substances 0.000 description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 235000019485 Safflower oil Nutrition 0.000 description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 235000010216 calcium carbonate Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 6
- 235000005713 safflower oil Nutrition 0.000 description 6
- 239000003813 safflower oil Substances 0.000 description 6
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 5
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 5
- 235000019743 Choline chloride Nutrition 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 5
- 229960002079 calcium pantothenate Drugs 0.000 description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 5
- 229960003178 choline chloride Drugs 0.000 description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 235000011147 magnesium chloride Nutrition 0.000 description 5
- 229940099596 manganese sulfate Drugs 0.000 description 5
- 239000011702 manganese sulphate Substances 0.000 description 5
- 235000007079 manganese sulphate Nutrition 0.000 description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 229960002816 potassium chloride Drugs 0.000 description 5
- 235000019172 retinyl palmitate Nutrition 0.000 description 5
- 229940108325 retinyl palmitate Drugs 0.000 description 5
- 239000011769 retinyl palmitate Substances 0.000 description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
- 239000011655 sodium selenate Substances 0.000 description 5
- 235000018716 sodium selenate Nutrition 0.000 description 5
- 229960001881 sodium selenate Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- 235000002906 tartaric acid Nutrition 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 229960001763 zinc sulfate Drugs 0.000 description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 4
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 235000005282 vitamin D3 Nutrition 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 229940021056 vitamin d3 Drugs 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- IERHLVCPSMICTF-ZAKLUEHWSA-N cytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-ZAKLUEHWSA-N 0.000 description 3
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000009969 flowable effect Effects 0.000 description 3
- -1 furans compound Chemical class 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 235000014666 liquid concentrate Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- 239000012744 reinforcing agent Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940083466 soybean lecithin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000199912 Crypthecodinium cohnii Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000544198 Muscisaxicola alpinus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 206010036600 Premature labour Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 240000000785 Tagetes erecta Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 230000008133 cognitive development Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 229960001781 ferrous sulfate Drugs 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229960002337 magnesium chloride Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 2
- 208000026440 premature labor Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000036364 Normal newborn Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000002003 electrode paste Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002658 luteins Chemical class 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- RMDJVOZETBHEAR-LQYWTLTGSA-N vitamin D5 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](CC)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C RMDJVOZETBHEAR-LQYWTLTGSA-N 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/80—Geriatric
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/801—Pediatric
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Dairy Products (AREA)
Abstract
本发明公开了用于促进婴儿视网膜健康和视觉发育的婴儿配方和相应使用它们的方法。该配方没有卵磷脂类和包含脂肪,蛋白质,碳水化合物,维生素,和矿物,包括二十二碳六烯酸和,在待喂基础上,至少约50mcg/升叶黄素,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1∶2至约10∶1。该配方还据信尤其可用于减少早产婴儿的早熟性视网膜病的危险。
Description
技术领域
本发明涉及用于促进婴儿的视网膜健康和视觉发育的包含二十二碳六烯酸和叶黄素的选择组合的婴儿配方。
背景技术
婴儿配方现常用于在生命初期提供补充或唯一的营养源。这些配方包含蛋白质,碳水化合物,脂肪,维生素,矿物,和其它营养物。它们作为粉末,待喂液体,和液体浓缩物而购得。
尽管许多婴儿配方提供可用于替代人乳的品质,但它们仍没有提供人乳中存在的同样高水平的营养。就这点而论,过去几年针对婴儿配方的许多研究涉及对人乳的天然成分的较好理解,并随后相应地,或至少在当前可用到的技术的可能程度上改进婴儿配方。
花生四烯酸和二十二碳六烯酸,例如已在人乳中得到确认和随后被加入合成婴儿配方。这些脂肪酸支持婴儿的大脑和视觉发育,且目前常存在于市售配方如婴儿配方,婴儿配方,和Special婴儿配方,都得自Ross严品分部,Abbott Laboratories,Columbus,Ohio,USA。
叶黄素也已在人乳中得到确认。尽管叶黄素目前不作为单独的成分被加入婴儿配方,但它作为常用于制备这些配方的一些天然油中的固有成分而以低浓度存在于婴儿配方中。叶黄素是一种也碰巧集中在眼的视网膜内的抗氧化剂。一般已知,饮食叶黄素可向个体提供眼健康益处,而且这种益处估计可扩大至接受来自人乳或补充婴儿配方的叶黄素的婴儿。
现在相信,叶黄素和二十二碳六烯酸的组合对于促进婴儿的视网膜健康和视觉发育可能特别重要。这些物质都存在于人乳且都已知集中在就其它方面而言健康的被试者的视网膜中。二十二碳六烯酸(DHA)(一种多不饱和脂肪酸)对眼内的氧化和变质所造成的损害高度敏感,而叶黄素是一种已知的抗氧化剂。通过将叶黄素加入婴儿配方,据信它不仅集中在视网膜内,而且可减少视网膜DHA的氧化降解和因此进一步促进婴儿的视网膜健康和视觉发育。
现已发现,由于婴儿配方的叶黄素的较低相对生物可利用率,婴儿配方中的叶黄素浓度必须明显高于人乳中的叶黄素浓度材料以实现相同的存在于哺乳婴儿的血浆叶黄素浓度。尽管现今的婴儿配方通常包含低于约20mcg/升的叶黄素,大多数固有地来自所加的脂肪和油,现已发现,这些叶黄素浓度必须超过约50mcg/升,优选约100mcg/升至约200mcg/升,这样使唯一地存在于哺乳婴儿的血浆叶黄素浓度得以加倍。
因此还已发现,如上所述包含叶黄素和DHA的组合的婴儿配方现在应该被配制成具有高于人乳所通常具有的比率(叶黄素/DHA)。叶黄素(mcg)与DHA(mg)的这些重量比现在应该是约1∶2至约10∶1。
本发明的综述
本发明涉及包含脂肪,蛋白质,碳水化合物,维生素,和矿物的婴儿配方,包括二十二碳六烯酸和至少约50mcg/升叶黄素,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1∶2至约10∶1。本发明还涉及使用该配方促进婴儿的视网膜健康和视觉发育的方法,包括减少婴儿的早熟性视网膜病的危险,和针对过多的自然或人工照明对婴儿眼的损害作用进行保护。
已经发现婴儿配方应该被制成具有至少50mcg/升的叶黄素浓度,这样它们才能产生与哺乳婴儿相同的血浆叶黄素浓度,即使人乳自身通常包含不超过约30mcg/升叶黄素。因此还发现,叶黄素(mcg)与DHA(mg)在婴儿配方中的重量比应该是约1∶2至约10∶1。叶黄素和二十二碳六烯酸的组合据信特别可用于促进婴儿视网膜健康和视觉发育,前提是,它们分别以足够量被设计到如本文所述的婴儿配方中。
附图的简要描述
图1是喂以人乳(HM)或包含不同浓度叶黄素的婴儿配方的婴儿组的叶黄素摄入(mcg/天)和相应血浆叶黄素浓度(mcg/dl)的图[CTRL具有14.6mcg叶黄素/升(不加入叶黄素,所有的叶黄素是各成分中所固有的);L1具有32.6mcg叶黄素/升(约18mcg/升的所加叶黄素,其余是固有的),L2具有52.6mcg叶黄素/升(约38mcg/升的所加叶黄素,其余是固有的)。
图2显示通过扫描视觉激发性电势(logMAR)针对4,8,和12周龄的猴所测定的视敏度。猴在12周喂料期内被喂以具有DHA和所加叶黄素(n=8)或没有加入叶黄素(n=8)的DHA。
本发明的详细描述
本发明婴儿配方包含脂肪,蛋白质,碳水化合物,矿物,和维生素,和包括叶黄素和二十二碳六烯酸的新型组合。本发明的婴儿配方和相应方法的这些和其它基本元素或限度在以下详细描述。
这里所用的术语″婴儿″是指不超过约一年龄的个体,和包括0至约4月大的婴儿,约4至约8月大的婴儿,约8至约12月大的婴儿,出生时低于2,500克的低出生重量婴儿,和低于约37周孕龄,通常约26周至约34周孕龄出生的早产婴儿。
这里所用的术语″婴儿配方″是指没有卵磷脂类的营养组合物,它被设计用于婴儿,包含足够的蛋白质,碳水化合物,脂肪,维生素,和矿物,这样在以足够量提供时有可能用作唯一的营养源。
除非另有规定,本文所用的术语″待喂″是指适用于喂给婴儿的液体形式的婴儿配方,包括再造粉末,稀释的浓缩物,和人造液体。
本文所用的表示为″mcg/升″或″mg/升″的所有浓度是指本发明婴儿配方内的成分浓度除非另有规定,以待喂计算或以喂料为基础。
除非另有规定,这里所用的所有的百分数,份数和比率基于总组合物的重量。涉及所列举的成分的所有这些重量基于活性含量和,因此,不包括可被包括在市售材料中的溶剂或副产物,除非另有规定。
本发明涉及单一特征或限度时的所有引用应该包括相应多个特性或限度,和反之亦然,除非另有规定或明显意味着与该参考所涉及的上下文相反。
这里所用的方法或工艺步骤的所有组合可按照任何顺序进行,除非另有规定或明显意味着与该参考所涉及的上下文相反。
本发明婴儿配方也可基本上没有本文所述的任何可有可无的或选择的基本成分或特点,前提是剩余配方仍包含本文所述的所有的所需成分或特点。关于这点,术语″基本上没有″是指,所选组合物包含低于功能量的可有可无的成分,通常低于0.1%重量,以及包括零%重量的这些可有可无的或选择的基本成分。
本发明婴儿配方和相应方法可包含本文所述的本发明基本元素和限度,以及任何其它的或可有可无的本文所述或以其它方式可用于营养配方场合的成分,组分,或限度,由它们组成,或基本上由它们组成。
叶黄素
本发明婴儿配方包含叶黄素,其浓度必须是至少约50mcg/升叶黄素。任何叶黄素源都适用于本文,前提是这种来源也已知或以其它方式适用于婴儿配方和与配方中的其它选择成分相容,其中叶黄素(mcg/升)与二十二碳六烯酸(mg/升)在配方中的重量比是约1∶2至约10∶1。
本发明婴儿配方中的叶黄素浓度是约50至约1150mcg/升,包括约75至约230mcg/升,以及包括约100至约200mcg/升,在待喂基础上计算。本文提及的所有的叶黄素浓度和比率在游离叶黄素基础上计算,除非另有规定。
叶黄素在婴儿配方中的量也必须选择这样叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1∶2至约10∶1,包括约1.5∶1至约9∶1,还包括约1.7∶1至约5∶1。
除非另有规定,本文所用的术语″叶黄素″是指一种或多种本文所述或以其它方式建议的游离的叶黄素,叶黄素酯,叶黄素盐,或其它叶黄素衍生物或相关结构。适用于本发明婴儿配方的叶黄素或叶黄素源包括游离的叶黄素以及酯,盐或其它衍生物或其相关结构,包括符合以下结构式的那些:
以上结构式包括叶黄素的一般结构和相关的衍生物或结构。游离叶黄素,例如,对应于其中R1和R2都是氢的结构式,和包括其顺式和反式异构体以及其盐,如,钠,钾。
适用于本发明婴儿配方的叶黄素酯包括具有以上结构式的任何叶黄素酯,其中R1和R2相同或不同,和是营养可接受的单价盐,氢或羧酸的酰基残基,前提是至少一个R1或R2是羧酸的酰基残基。合适的叶黄素酯也包括,顺式和反式异构体。R1和R2部分是饱和或不饱和C1至C22脂肪羧酸的残基,非限定性例子包括甲酸,乙酸,丙酸,丁酸,戊酸,己酸,辛酸,癸酸,月桂酸,肉豆蔻酸,棕榈酸,硬脂酸,和油酸。
本文所用的叶黄素包括已知用于或以其它方式作为可接受源用于口服营养物,包括婴儿配方的任何天然或合成源。叶黄素源可作为各个成分或与其它材料或来源,包括来源如多维生素预混物,混合的类胡萝卜素预混物,纯叶黄素源,和来自婴儿配方中的其它脂肪或油组分的固有叶黄素进行任何组合而提供。本文所述的叶黄素浓度和比率基于所加的和固有的叶黄素源而计算。本发明婴儿配方优选包含基于总叶黄素至少约25%,更优选约50%至约95%,重量的所加叶黄素,其余是伴随所加的脂肪和油的固有叶黄素。
适用于本文的一些合适的叶黄素源的非限定性例子包括结晶叶黄素,可得自Kemin Foods,Des Moines,Iowa,USA;和叶黄素酯,由Cognis,Cincinnati,Ohio,USA提供。
本发明婴儿配方包括包含游离叶黄素和玉米黄素的单一源组合的优选实施方案,为来自万寿菊花(万寿菊)的纯化结晶提取物,其中游离叶黄素占该组合的85%至95%重量和玉米黄素占该组合的约5%至约15%重量。优选的叶黄素-玉米黄素组合以牌得自KeminFoods,Des Moines,Iowa,USA。
二十二碳六烯酸(DHA)
本发明婴儿配方包含二十二碳六烯酸,一种具有22个碳链长的有机羧酸,具有自甲基端(22:6n-3)的第三个碳开始的6个双键。任何二十二碳六烯酸源适用于本文,前提是这种来源也已知用于或以其它方式适用于婴儿配方和与该配方中的其它选择成分相容。
本发明婴儿配方中的二十二碳六烯酸浓度必须选择使得叶黄素与二十二碳六烯酸的所得重量比落入本文所定义的范围内。这些浓度最通常是约36至360mg/升,包括约50至约144mg/升,以及包括约72至约130mg/升,在待喂基础上计算。
二十二碳六烯酸可作为游离脂肪酸或作为可在向婴儿喂入时或之后以其它方式提供这些游离脂肪酸的来源的化合物或材料,包括二十二碳六烯酸的非卵磷脂类和甘油酯(单-,二,三-)而被加入婴儿配方。多不饱和脂肪酸和其来源描述于U.S.专利6,080,787(Carlson,等人)和U.S.专利6,495,599(Auestad,等人),其说明书是引入通过参考文件在此。合适的二十二碳六烯酸源的一些非限定性例子包括鱼油,藻油,其它单细胞油,和其组合。
除了本文所述的二十二碳六烯酸,本发明婴儿配方可进一步包含其它长链多不饱和脂肪酸如花生四烯酸(20:4n-6),二十碳五烯酸或EPA(20:5n-3),亚油酸(18:2n-6),γ-亚麻酸或GLA(18:3n-6),α-亚麻酸(18:3n-3),二高-γ-亚麻酸或DHGLA(20:3n-6),α-亚麻酸(18:3n-3),十八碳四烯酸(18:4n-3),和其组合。这些可有可无的长链多不饱和脂肪酸也可作为游离脂肪酸或作为可在向婴儿喂入时或之后以其它方式提供这些游离脂肪酸的来源的化合物或材料,包括二十二碳六烯酸的非卵磷脂类和甘油酯(单-,二,三-)而被配制到婴儿配方中。
其它营养物
本发明婴儿配方包含脂肪,蛋白质,碳水化合物,矿物,和维生素,它们的种类和量都选择使得满足预期的婴儿群的饮食需要。
许多不同的来源和种类的碳水化合物,脂肪,蛋白质,矿物和维生素是已知的和可用于本发明婴儿配方,前提是这些营养物与所加的成分在所选的配方中相容和以其它方式适用于婴儿配方。
适用于本发明婴儿配方的碳水化合物可以是简单的或复杂的,含乳糖的或无乳糖的,或其组合,非限定性例子包括水解,原样,天然和/或化学改性的谷物淀粉,麦芽糖糊精,葡萄糖聚合物,蔗糖,谷类浆,谷类浆固体,米或马铃薯衍生的碳水化合物,葡萄糖,果糖,乳糖,高果糖谷类浆和难消化的低聚糖如呋喃低聚糖(FOS),半乳低聚糖(GOS),和其组合。
适用于本发明婴儿配方的蛋白质包括水解,部分水解,和非水解或原样的蛋白质或蛋白质源,和可衍生自任何已知的或在其它方面合适的来源如乳(如,酪蛋白,乳清),动物(如,肉,鱼),谷类(如,米,谷物),植物(如,大豆),或其组合。
本文所用的蛋白质也可包括,或完全是或部分被替换为,已知用于或以其它方式适用于婴儿配方的游离氨基酸,非限定性例子包括丙氨酸,精氨酸,天冬酰胺,卡尼汀,门冬氨酸,胱氨酸,谷氨酸,谷酰胺,甘氨酸,组氨酸,异亮氨酸,亮氨酸,赖氨酸,蛋氨酸,苯基丙氨酸,脯氨酸,丝氨酸,牛磺酸,苏氨酸,色氨酸,牛磺酸,酪氨酸,缬氨酸,和其组合。这些氨基酸最通常以其L-形式使用,尽管相应D-异构体也可使用(如果营养上相当)。外消旋或异构体混合物也可使用。
适用于本发明婴儿配方的脂肪包括椰子油,大豆油,玉米油,橄榄油,红花油,高油酸红花油,藻油,MCT油(中链甘油三酯),向日葵油,高油酸向日葵油,棕榈和棕榈核油,棕榈油精,低芥酸菜子油,海底油,棉籽油,和其组合。
适用于本发明婴儿配方的维生素和类似其它成分包括维生素A,维生素D,维生素E,维生素K,维生素B1,维生素B2,维生素B6,维生素B12,烟酸,叶酸,泛酸,生物素,维生素C,胆碱,肌醇,盐和其衍生物,和其组合。
适用于本发明婴儿配方的矿物包括钙,磷,镁,铁,锌,锰,铜,铬,碘,钠,钾,氯根,和其组合。
婴儿配方优选包含按照目标消费者或使用者人群所用的相关婴儿配方指南(一个例子是婴儿配方法案,21U.S.C.350(a)章)的营养物。
本发明婴儿配方还包括包含下表所述的碳水化合物,脂肪,和蛋白质浓缩物的那些实施方案。
表1:婴儿配方营养物1
1.所有的数字值可使用词″约″修饰
2.来自待喂液体,再造粉末,或稀释的浓缩物
本发明婴儿配方包括每100kcal配方包含一种或多种以下成分的那些实施方案:维生素A(约250至约750IU),维生素D(约40至约100IU),维生素K(大于约4mcg),维生素E(至少约0.3IU),维生素C(至少约8mg),维生素B1(至少约8g),维生素B12(至少约0.15g),烟酸(至少约250g),叶酸(至少约4g),泛酸(至少约300g),生物素(至少约1.5g),胆碱(至少约7mg),和肌醇(至少约4mg)。
本发明婴儿配方还包括每100kcal配方包含一种或多种以下成分的那些实施方案:钙(至少约50mg),磷(至少约25mg),镁(至少约6mg),铁(至少约0.15mg),碘(至少约5g),锌(至少约0.5mg),铜(至少约60g),锰(至少约5g),钠(约20至约60mg),钾(约80至约200mg),和氯化物(约55至约150mg)。
可有可无的成分
本发明婴儿配方可进一步包含可在用于目标婴儿人群时改变组合物的物理,化学,美学或处理特性或用作药物或其它的营养组分的其它可有可无的成分。许多这些可有可无的成分是已知的或以其它方式适用于营养产物和也可用于本发明婴儿配方,前提是这些可有可无的材料与本文所述和以其它方式适用于婴儿配方的基本材料相容。
这些可有可无的成分的非限定性例子包括防腐剂,其它的抗氧化剂,乳化剂,缓冲剂,着色剂,香料,核苷酸和核苷,前生命物质,乳铁蛋白和相关衍生物,增稠剂和稳定剂,和等等。
产品形式
本发明婴儿配方可被制成适用于婴儿的任何产品形式,包括可复水粉末,待喂液体,和可稀释的液体浓缩物,这些产品形式都是营养和婴儿配方领域所熟知的。
本发明婴儿配方可具有适用于预期婴儿人群的任何热量密度,或在粉末实施方案的再造或在液体浓缩物实施方案的稀释时提供这种密度。最常用于本发明婴儿配方的热量密度一般是至少约18kcal/fl oz(609kcal/升),更通常约20kcal/fl oz(675-680kcal/升)至约25kcal/fl oz(820kcal/升),甚至更通常约20kcal/fl oz(675-680kcal/升)至约24kcal/floz(800-810kcal/升)。一般,22-30kcal/fl oz,最通常约22-24kcal/fl oz配方更常用于早产的低出生体重婴儿,和20-21kcal/fl oz(675-680至700kcal/升)配方更常用于正常生产的婴儿。较高热量喂料可用于低出生体重的早产婴儿;这些喂料通常是约27kcal/fl oz(90-95kcal/升)至约30kcal/fl oz(1000-1015kcal/升)。
对于本发明的粉末实施方案,这些粉末通常是可流动的或基本上可流动的颗粒组合物,或至少颗粒状的可容易地用勺子或类似其它设备取用和测量的组合物的形式,其中组合物可容易由预期使用者用合适的含水流体,通常水进行再造;以形成用于即时口服或进入用途的液体营养配方。关于这点,″即时″用途一般是指在约48小时内,最通常在约24小时内,优选在再造之后不久。这些粉末实施方案包括喷雾干燥,烧结,干法搅拌或其它已知的或以其它方式有效的颗粒形式。产生适用于一份食物体积所需的营养粉末的量可不同。
本发明婴儿配方可包装和密封在单或多用途容器,并随后在环境病况下储存最高约36个月或更长,更通常约12至约24个月。对于多用途容器,这些包装可被最终用户打开并随后盖上以重复使用,前提是盖上的包装随后在环境病况下储存(如,避免极端温度)和内容物在约一个月左右使用。
视网膜健康和视觉发育
本发明还涉及供给该配方以促进婴儿的视网膜健康和视觉发育的方法。在该特殊方法中,婴儿配方作为营养的唯一来源,主要来源,或补充来源而供给正常生产或早产的婴儿,其中配方包含脂肪,蛋白质,碳水化合物,维生素,和矿物,包括二十二碳六烯酸和至少约50mcg/升叶黄素,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1∶2至约10∶1。这种方法可应用于本文所述或以其它方式建议的任何配方实施方案。
该特殊方法因此应该向婴儿提供有效量叶黄素以产生所述益处,包括约7至约300mcg/kg/天,包括约14至约220mcg/kg/天,以及包括约22至约150mcg/kg/天(叶黄素/kg体重婴儿),其中叶黄素与二十二碳六烯酸的重量比保持在本文所述的比率内。
眼和视觉发育在生命的第一年快速地进行。出生时,婴儿仅能看见大约25-30cm远的高对比度物体。在随后6个月中,婴儿的视网膜充分发育,能够看见和辨别小的细节。而且随着婴儿视觉的发育(大多数发生在第一年内),婴儿变得更能够使用新发育的视力通过视觉刺激而认识。对于婴儿,该视觉认识随后在大脑和认知发育中起着重要的作用,尤其在生命的头2-3年内。
通过促进婴儿的视网膜健康和视觉发育,本发明婴儿配方也可帮助儿童发育其通过眼的显影视网膜而尽可能视觉认识,和潜在地促进与早期视觉刺激有关的大脑和认知发育的能力。通过早期视觉刺激,本发明婴儿配方因此可用于促进婴儿的视觉发育,和因此可用于促进次要益处如相关的认知和大脑发育。
本发明的这种特殊方法尤其可用于早产婴儿,帮助促进正常视觉的发育,因此减少追赶其足月儿对应组所产生的发育差异所需的时间。
早熟性视网膜病
本发明婴儿配方在向早产婴儿喂料时尤其可用于减少早熟性视网膜病的危险。按照这种方法,婴儿配方作为营养的唯一来源,主要来源,或补充来源而供给,其中配方包含脂肪,蛋白质,碳水化合物,维生素,和矿物,包括二十二碳六烯酸和至少约50mcg/升叶黄素,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1∶2至约10∶1。这种方法可应用于本文所述或以其它方式建议的任何配方实施方案。
早熟性视网膜病是一种通常影响早产婴儿的症状,最通常特征在于眼中的视网膜管的发育异常,可能由于次于高氧紧张的氧化应急所引起。该痛苦可能发生至不同程度,从对视觉影响极小或没有影响的轻微血管受累,至导致失明的部分或完全视网膜剥离。历史上,用于合适案例的治疗包括激光治疗以及低温治疗。
该特殊方法因此应该向婴儿提供有效量叶黄素以产生所述益处,包括约7至约300mcg/kg/天,包括约14至约220mcg/kg/天,以及包括约22至约150mcg/kg/天(叶黄素/kg体重婴儿),其中叶黄素与二十二碳六烯酸的重量比保持在本文所述的比率内。
制造方法
本发明婴儿配方可通过任何已知的或以其它方式有效的适用于制造和配制婴儿配方或类似其它配方的技术而制备,不同之处可取决于所需婴儿配方的变量如所选的产品形式,成分组合,包装和容器选择,和等等。婴儿营养配方或制造领域的普通技术人员容易地确定和应用用于任何给定配方的这些技术和变化。
本发明婴儿配方,包括以下描述的例举配方,可因此通过任何各种已知的或以其它方式有效的配制或制造方法而制备。这些方法最通常包括起始形成包含碳水化合物,蛋白质,脂类,稳定剂或其它配制助剂,维生素,矿物,或其组合的含水淤浆。淤浆被乳化,糊化,匀化,和冷却。各种其它溶液,混合物,或其它材料可在进一步处理之前,过程中或之后被加入所得乳液。该乳液可随后被进一步稀释,热处理,和包装以形成待喂或浓缩物液体,或它可被热处理和随后处理和包装成可复水粉末,如,喷雾干燥,干法搅拌,烧结。
用于制造营养配方的其它合适的方法例如描述于U.S.专利6,365,218(Borschel,等人),U.S专利6,589,576(Borschel,等人),U.S.专利6,306,908(Carlson,等人),U.S.专利申请20030118703 A1(Nguyen,等人),其说明书在此作为参考并入本发明。
实验
该实验的目的是评估动物的视觉灵敏度的变化,这些动物被喂以包含DHA或DHA和加入的叶黄素的婴儿配方。十六只猴在其生命的头12周内被喂以两种所定义的婴儿配方之一。一种是对照配方婴儿配方,可得自Abbott Laboratories,ColumbusOhio,和另一种是包括婴儿配方作为基料,但加入包含叶黄素的类胡萝卜素的实验配方。配方包括以下:
基础配方(婴儿配方)包含水,脱脂乳,乳糖,高油酸红花油,大豆油,椰子油,乳清蛋白质浓缩物;C.cohnii油,M.alpina油,柠檬酸钾,碳酸钙,抗坏血酸,单-和二甘油酯,大豆卵磷脂,角叉菜胶,氯化钾,氯化镁,氯化钠,硫酸亚铁,氯化胆碱,洒石酸氢胆碱,牛磺酸,m-肌醇,d-α-生育酚基乙酸酯,L-卡尼汀,硫酸锌,烟酸酰胺,泛酸钙,维生素B2,维生素A棕榈酸酯,硫酸铜,氯化维生素B 1盐酸盐,维生素B6盐酸盐,β-胡萝卜素,叶酸,硫酸锰,叶醌,生物素,硒酸钠,维生素D3,维生素B 12和核苷酸(腺苷5′-单磷酸盐,胞苷5′-单磷酸盐,鸟嘌呤核甙5’-单磷酸二钠,尿嘧啶核苷5’-单磷酸二钠)。
猴从出生到生命的第12周无规地接受实验(n=8)或对照(n=8)配方。动物不接受来自它们母亲的任何乳。婴儿和目前在出生时分开。在研究过程中,猴每天12小时暴露于具有日照的强度和光谱特性的光以模拟婴儿可能经受的光诱导的氧化应急。在研究过程中,评估猴的几个参数,包括血浆叶黄素浓度和扫描视觉激发性电势(VEP)。
血浆叶黄素
在出生时(0周龄)被喂以对照和实验配方的猴之间,叶黄素,番茄烯,和β-胡萝卜素的血浆浓度没有明显差异。在4(p<0.001),8(p<0.001),和12(p<0.001)周龄时,喂以实验配方的猴的血浆叶黄素浓度明显高于喂以对照配方的猴。类似地,在4(p<0.001),8(p<0.001),和12(p<0.001)周时,实验组的血浆番茄烯浓度明显高于对照组。在4(p=0.005)和8(p=0.010),但不12(p=0.052)周龄时,实验配方组的血浆β-胡萝卜素浓度明显高于对照配方组。
视敏度
在生命的4,8,和12周时,评估猴的视觉灵敏度的变化。视敏度通过扫描视觉激发性电势(VEP)测定,该方法是本领域熟知的用于测量婴儿的视觉激发性电势的方法。视敏度通过确定由视皮质激发可测量的响应的最小空间频率高对比度光栅而测定。来自原有皮层可视面积的VEP使用小银盘EEG电极记录,所述电极使用水溶性电极糊放置在头皮上。婴儿被固定在试验者的膝盖上,同时注视着显示相反转黑白光栅的视频监控器。如果必需,使用小的悬挂玩具将婴儿的注意力集中于屏幕的中心。在每一″扫描″过程中,光栅的空间频率在几秒记录期过程中逐步从高于受试者的敏度阈值降低至低于该阈值。VEP响应的第二谐波的振幅反映与激发物反转速率相关的响应,将它作为空间频率的函数进行作图以确定受试者的敏度阈值(Neuringer M,Jeffrey BG:视觉发育:神经系统基础和新评估方法。J Pediatr 2003;143:S87-S95)。
该研究的VEP得分汇总在图1中。较低VEP(logMAR)得分表示较好的视敏度。尽管所有的猴在12周测试期内VEP得分下降(即,视敏度提高),正如预期,但在8周时的实验基团(加入叶黄素+DHA配方)的VEP得分意外低于对照组(没有加入叶黄素的DHA配方)(4周,p=0.412,等)
数据表明,喂以实验配方的婴儿猴在生命第8周时加速发育-具体地在由VEP值度量的视敏度上。为了将数据外推至人类婴儿,4,8,和12周龄猴的眼发育分别对应于4,8,和12月的人类婴儿得到眼发育。该数据因此表明,甚至对于人类婴儿,实验配方在生命的约4和约12月时提高视敏度。
实施例
以下实施例表示本发明范围内的特定实施方案,每一实施方案仅为了说明目的而给出且不被理解为对本发明的限定,可在不背离本发明的主旨和范围的情况下进行许多变化。所有的例举量基于组合物总重的重量百分数,除非另有规定。
实施例1.1-1.3
以下是本发明乳基,待喂,婴儿配方的实施例,包括使用和制造该配方的方法。每一批料的配方成分在下表中列出。
1.预混物包含(每65g)19.8g牛磺酸,14.4g肌醇,6.7g硫酸锌,4.2g烟酸酰胺,2.6g泛酸钙,2.3g硫酸亚铁,0.8g硫酸铜,0.6g维生素B1,0.3g维生素B2,0.26g维生素B6,0.1g叶酸,0.07g硫酸锰,0.03g生物素,0.025g硒酸钠,0.002g维生素B12
2.预混物包含(每21g)4.0gα-维生素E乙酸酯,0.8g维生素A棕榈酸酯,0.05§叶醌,0.006g维生素D3
3.预混物包含(每133g):23g洒石酸氢胆碱,15g 5′-CMP,11g5′-GMP,10g 5′-UMP,6g 5′-AMP
例举配方可通过制造至少三种单独的淤浆,随后共混在一起,热处理,标准化,包装和消毒而制备。起始,碳水化合物-矿物淤浆通过在65-71摄氏度下将乳糖溶解在水中,随后加入氯化镁,柠檬酸钾,氯化钾,氯化胆碱,和柠檬酸而制备。所得淤浆在55-65摄氏度下搅拌不超过8小时,随后与其它所制淤浆共混。
蛋白质-脂肪淤浆通过将高油酸红花油,大豆油,和椰子油在55-60摄氏度下合并,随后加入维生素ADEK预混物,单-和二甘油酯,卵磷脂,角叉菜胶,维生素A,ARA油,和DHA油而制备。随后加入乳清蛋白质和碳酸钙。所得蛋白质-油淤浆在40-43摄氏度下搅拌不超过2小时,随后与其它所形成的淤浆共混。
碳水化合物-矿物淤浆随后与水和非脂肪干乳结合和搅拌10分钟。随后加入蛋白质-油淤浆并将所得混合物搅拌至少10分钟。叶黄素和β-胡萝卜素随后被加入该共混物和搅拌至少15分钟。所得共混物的pH使用1N氢氧化钾调节至6.68-6.75。
在等待不低于1分钟也不大于2小时之后,所得共混物被加热至71-82标准化和在真空下脱气,通过单步匀化器在900-1100psig下乳化,并随后加热至99-110摄氏度,并随后再次加热至146摄氏度约5秒。使加热的共混物经过一个闪蒸冷却器以使温度降至99-110摄氏度并随后通过板冷却器以使温度进一步降至71-76摄氏度。冷却的共混物随后在3900-4100/400-600psig下匀化,并随后在74-80摄氏度下保持16秒,并随后冷却至1-7标准化。取样进行微生物和分析测试。混合物在搅拌下保持。
水溶性维生素(WSV)溶液和抗坏血酸溶液分开制备并加入处理的共混淤浆。维生素溶液通过在搅拌下将以下成分加入9.4kg水中而制备:柠檬酸钾,硫酸亚铁,WSV预混物,L-卡尼汀,维生素B2,和核苷酸-胆碱预混物。抗坏血酸溶液通过将柠檬酸钾和抗坏血酸加入足够量的水中以溶解这些成分而制备。维生素和抗坏血酸溶液随后加入该共混物,并将共混物的pH使用45%氢氧化钾溶液调节至7-10。
基于质量控制试验的分析结果,在搅拌下将合适量的水加入批料中以实现所需总固体。可调节产物pH以实现最佳产物稳定性。成品随后被放在合适的容器中和进行终末灭菌。
所得配方作为唯一的营养来源喂给处于生命头6至12个月的婴儿,向每一婴儿提供7-300μg/kg/天的叶黄素。该配方提供本文所述的改进的视网膜健康和视觉发育。
实施例2.1-2.3
以下是本发明大豆基,粉末,婴儿配方的实施例,包括使用和制造该配方的方法。每一批料的配方成分在下表中列出。
制备例举粉末的第一步是制备油共混物。大豆油,椰子油和高油酸红花油在合适的容器或罐中在60-65标准化下在搅拌下合并。棕榈酸抗坏血酸基酯和混合的维生素Es被加入罐,随后加入油可溶维生素预混物,都在搅拌下进行。将B-胡萝卜素(BASF,Mount Olive,NewJersey),和叶黄素(Kemin,Des Moines,Iowa)加入油共混物和搅拌直至充分分散。在制造工艺过程中,大豆蛋白质分离物和蛋氨酸随后被加入油共混物,并将所得混合物在54.0-60摄氏度下搅拌和保持,直至以后使用。
随后制备碳水化合物-矿物淤浆。氯化钾,氯化钠,氯化镁,和碘化钾被加入60-65摄氏度水中,随后加入二和三-磷酸钙,都在搅拌下进行。在制造工艺过程中,随后在搅拌下加入谷物浆,并将淤浆保持在54-60摄氏度下直至以后使用。
碳水化合物-矿物淤浆被加入油共混物。根据需要加入补给水。ARA和DHA油被加入共混物。所得混合物的pH使用KOH溶液调节至6.75-6.85.调节的混合物随后在54-6摄氏度下在搅拌下保持至少15分钟。
所得混合物随后加热至74-79摄氏度和在真空下脱气,通过单步匀化器在0-2.76MPa下乳化,在6.2-7.6MPa和2.1-3.4MPa下经过一个两步匀化器。匀化混合物在73-79摄氏度下保持16秒并随后冷却至1-7摄氏度。取样进行微生物和分析测试。混合物在搅拌下保持。
碳酸钙溶液可制备用于调节混合物(如果超出规格标准)的钙水平。
制备出包含水可溶维生素预混物以及痕量矿物和牛磺酸的维生素储备溶液。柠檬酸钾和硫酸亚铁加入37-66摄氏度的水中。随后加入维生素预混物并将混合物搅拌。加入氯化胆碱和卡尼汀并随后将所需量的该维生素混合物加入批料中。
制备出抗坏血酸溶液并在搅拌下在至少10分钟内慢慢加入批料中。批料随后预加热至74-79摄氏度。批料随后在107-110摄氏度下使用直接蒸汽注射而保持5秒。批料随后冷却至71-82摄氏度,然后被抽吸至喷雾干燥器和干燥至可流动的粉末。批料随后包装在合适的容器中和在低于2.0%氧的预留空间下密封。
该例举粉末用水再造至热量密度676kcal/升。所得液体配方作为唯一的营养来源喂给处于生命头6至12个月的婴儿,提供7-300μg/kg/天的叶黄素。该配方提供本文所述的改进的视网膜健康和视觉发育。
实施例3.1-3.3
以下是本发明乳基,粉末,婴儿配方的实施例,包括使用和制造该配方的方法。每一批料的配方成分在下表中列出。
1.预混物向产品提供71gm乙酸d-α-生育酚基酯,7.29gm维生素A棕榈酸酯,0.422gm叶醌,和0.051gm维生素D3。
2.预混物向产品提供252gm牛磺酸,183gm肌醇,84.5gm硫酸锌,53.8gm烟酸酰胺,32.6gm泛酸钙,29gm硫酸亚铁,10.1gm硫酸铜,8.4gm维生素B1,3.7gm维生素B2,3.4gm维生素B6(HCl),1.1gm叶酸,1.0gm硫酸锰,0.3gm生物素,0.2gm硒酸钠,和0.03gm维生素B 12。
3.预混物向产品提供188gm洒石酸氢胆碱,118gm胞苷5′-单磷酸盐,92gm鸟嘌呤核甙5’-单磷酸二钠,80gm尿嘧啶核苷5’-单磷酸二钠,和51gm腺苷5′-单磷酸盐。
该粉末配方通过制备至少两种淤浆,随后共混在一起,热处理,标准化,喷雾干燥和包装而制成。起始,碳水化合物-矿物淤浆通过将乳糖溶解在66-76摄氏度的水中而制备(45-50%固体)。随后加入谷物浆固体并溶解,随后加入氯化镁,柠檬酸钾,氯化钠,氯化胆碱,和柠檬酸钠,都在搅拌下进行。在制造工艺过程中,所得碳水化合物-矿物淤浆在54-60摄氏度下在搅拌下保持直至以后使用。
蛋白质-脂肪淤浆通过将高油酸红花油,椰子油,大豆油,和MCT油在40.5-49摄氏度下合并,随后加入棕榈酸抗坏血酸基酯,混合的维生素E,维生素A棕榈酸酯,和维生素ADEK预混物而制备,都在搅拌下进行。随后在搅拌下加入叶黄素(Kemin,Des Moines,Iowa)。乳清蛋白质浓缩物被随后加入淤浆中,随后加入碳酸钙和磷酸钙三碱性,都在搅拌下进行。将成品蛋白质-脂肪淤浆在中度搅拌下在54-60摄氏度下保持不超过12小时直至与其它所制淤浆共混。
碳水化合物-矿物淤浆被转移至罐中,其中加入足够量的水以产生约50%固体的最终共混物淤浆。非脂肪干乳随后加入该共混物中和增溶。随后加入蛋白质-脂肪淤浆并将整个共混物淤浆搅拌至少15分钟。所得共混物保持在60-65摄氏度下。共混物pH使用1N KOH调节至6.7-6.9。
在等待不低于1分钟也不大于2小时之后,所得共混物被加热至71-79标准化,在2.75-4.1MPa下乳化,并随后使用直接蒸汽注射加热至115-127摄氏度约5秒。加热乳液随后被快速冷却至87-99摄氏度,和在9.7-11.0/2.75-4.1MPa下匀化。匀化淤浆随后冷却至1.6-7.2标准化.取样进行微生物和分析测试。混合物在搅拌下保持。
维生素-痕量矿物溶液通过将以下成分在搅拌下加入所需量的水中而制备:柠檬酸钾,硫酸亚铁,卡尼汀,维生素和痕量矿物预混物,肌醇,和核苷酸和洒石酸氢胆碱预混物。维生素-痕量矿物溶液随后在搅拌下加入匀化淤浆中。
抗坏血酸溶液通过将柠檬酸钾和抗坏血酸在搅拌下加入水中,并随后将含水混合物在搅拌下加入匀化淤浆中而制备。
产物被预加热至65.5-77摄氏度。产物随后在82-90.5摄氏度下保持5秒,然后快速冷却至71-82摄氏度和泵吸至喷雾干燥器。产物被喷雾干燥以生成所需自由流动粉末。所得粉末在氮气下包装以使产物稳定性和香味最佳化。
该例举粉末用水再造至热量密度676kcal/升。所得液体配方作为唯一的营养来源喂给处于生命头6至12个月的婴儿,提供7-300μg/kg/天的叶黄素。该配方提供本文所述的改进的视网膜健康和视觉发育。
实施例4.1-4.3
以下是本发明浓缩物人乳增强剂液体的实施例,包括使用和制造该配方的方法。每一批料的配方成分在下表中列出。
将在前表中列出的成分合并和处理以形成本发明的浓缩物人乳增强剂实施方案。以下描述一种制备这种实施方案的方法。
起始中间体共混物通过将规定量的椰子油,MCT油,大豆油,DHA油和AA油加热至32-37摄氏度而制备,都在搅拌下进行。大豆卵磷脂乳化剂在搅拌下加入受热的共混物中并溶解。随后在搅拌下将维生素A,D5和K,天然维生素E,和叶黄素加入显色共混物中。乳蛋白质分离物(25.8kg)和规定量的超微化磷酸三钙和碳酸钙被加入该共混物。所得中间体共混物在26-48摄氏度下在中度搅拌下保持不超过6小时,然后加入以下描述的含水蛋白质共混物中。
含水蛋白质共混物随后通过将573kg成分水在48-60摄氏度下加热,并随后在搅拌下向其中加入乳蛋白质分离物(38.8kg)和规定量的乳清蛋白质浓缩物而制备。然后,和在搅拌下,以上描述的整个中间体共混物被加入含水蛋白质共混物。以下成分随后按照以下顺序被加入所得共混物:柠檬酸钾,磷酸二钾,磷酸单钾,磷酸镁,氯化钠,氯化钾,碘化钾和蔗糖。在不低于5分钟之后,共混物pH使用1N KOH溶液调节至6.60-6.80,和然后保持在51-60摄氏度下,不超过2小时,然后进一步处理。
pH调节的共混物随后使用一个或多个在线匀化器在压力1000-4000psig下匀化,有或没有100-500psig的第二步匀化,随后使用HTST(高温短时间,74摄氏度,16秒)或UHTST(超-高温短时间,132-154摄氏度,5-15秒)工艺热处理。UHTST或HTST通常根据配方中每一成分的生物负担而选择。在合适的热处理之后,将批料在冷却板中冷却至1.0-5.0摄氏度并随后转移至冷藏存料罐,其中进行分析测试并随后根据成品技术条件进行标准化,包括加入抗坏血酸溶液和水溶性维生素和痕量矿物溶液,都在加入至以前描述的冷冻批料之前分开制备。
抗坏血酸溶液通过在搅拌下将规定量的抗坏血酸加入11.1kg 1NKOH溶液中而制备。水溶性维生素和痕量矿物溶液通过将25.2kg成分水加热至37摄氏度至48摄氏度而制备。将水可溶维生素和痕量矿物加入作为包含m-肌醇,牛磺酸,烟酸酰胺,硫酸锌,泛酸钙,硫酸亚铁,硫酸铜,维生素B2,维生素B1盐酸盐,维生素B6盐酸盐,叶酸,硫酸锰,生物素,硒酸钠,和维生素B12的预混物的水中。如上所述,溶液都随后被加入冷冻批料中,都在搅拌下进行。作为批料标准化的一部分,将合适量的成分稀释水随后加入批料中,达到目标总固体含量31%,和pH用1N KOH溶液调节至7.1。将该批料填充到包含5ml产物的尺寸合适的容器中。
将该例举人乳增强剂浓缩物与人乳(具有20-25ml人乳的5ml浓缩物)合并。增强人乳随后喂给早产婴儿以提供7-300μg/kg/天的叶黄素。该配方提供本文所述的改进的视网膜健康和视觉发育,包括减少早熟性视网膜病的危险。
实施例5.1-5.3
该实施例说明本发明的待喂,早产婴儿配方实施方案。该配方类似于具有铁过早婴儿配方的Special一种可得自Abbott Laboratories,Columbus,Ohio的早产婴儿配方,除了增加叶黄素浓度和随后增加叶黄素与二十二碳六烯酸的比率。
早产婴儿配方包括脱脂乳,谷类浆固体,乳糖,中链甘油三酯,乳清蛋白质浓缩物,大豆油,椰子油,C.cohnii油(源二十二碳六烯酸),M.alpina油(花生四烯酸源),磷酸钙,碳酸钙,柠檬酸钾,抗坏血酸,氯化镁,大豆卵磷脂,单-和二甘油酯,m-肌醇,柠檬酸钠,角叉菜胶,硫酸亚铁,洒石酸氢胆碱,牛磺酸,氯化胆碱,烟酸酰胺,d-α-生育酚基乙酸酯,L-卡尼汀,硫酸锌,氯化钾,二元磷酸钾,泛酸钙,硫酸铜,维生素A棕榈酸酯,维生素B2,氯化维生素B 1盐酸盐,维生素B6盐酸盐,叶酸,β-胡萝卜素,硫酸锰,生物素,叶醌,硒酸钠,维生素D3,维生素B12和核苷酸(胞苷5′-单磷酸盐,鸟嘌呤核甙5’-单磷酸二钠,尿嘧啶核苷5’-单磷酸二钠,腺苷5′-单磷酸盐)。
以上提及的成分通过常规方法配制在一起以提供以下营养分布:
将例举待喂配方(热量密度812kcal/升)喂给早产婴儿以提供7-300mcg/kg叶黄素/天。所喂给的配方如本文所述提高眼健康,和尤其可应用于早产婴儿以减少早熟性视网膜病的危险和帮助保护眼不受自然或人造光,尤其双重光的损害。
实验
对母乳喂养的婴儿的血浆叶黄素浓度与配方喂养婴儿的血浆叶黄素浓度进行比较研究。后者接受叶黄素浓度32.6mcg/升(L1),52.6mcg/升(L2),或14.6mcg/升(CTRL)的三种配方之一。研究组和所得血浆叶黄素浓度汇总在下表。
值表示为中值±SEM,(范围)栏中具有上标没有普通字母的n个值不同(p<0.05)。实际的p值参见文本。使用Kruskal-Wallis试验在配方组之间进行统计比较。使用Wilcoxon等级汇总试验在配方组和人乳组之间进行比较。
血浆叶黄素浓度(在研究的第56天)用作研究中的基本变数。主要对比L2和CTRL配方组之间在血浆叶黄素浓度上的差异。次要比较包括配方组(CTRL,L1,L2)之间在血浆叶黄素浓度上的差异和以及配方组和人乳组之间的差异。总共85个婴儿(CTRL,n=18;L1,n=22;L2,n=19;HM,n=26)在第56天时的血浆叶黄素浓度用于这些分析和结果在下表中记录为中值±SEM。
L2配方组中的婴儿的叶黄素血浆浓度(p<0.05)明显高于L1和CTRL配方组中的婴儿。血浆叶黄素在L1和CTRL配方组之间不同。人乳组的血浆叶黄素浓度高于CTRL(p0.0001),L1(p0.0001),和L2(p=0.0052)配方组。血浆叶黄素浓度明显与叶黄素摄入相关(r=0.436,p=0.0014)。来自该研究的叶黄素摄入和血浆响应还汇总在图1中。
研究数据表明,婴儿配方的叶黄素意外地不如人乳可生物利用(参见图1)。就这点而论,为了使婴儿配方在婴儿中产生类似于人乳喂养所产生的血浆叶黄素浓度,婴儿配方必须配制成包含至少约50mcg/升叶黄素,优选100mcg/升至约200mcg/升。
Claims (17)
1.一种婴儿配方产品,包含脂肪,蛋白质,碳水化合物,维生素,和矿物,包括二十二碳六烯酸和,在待喂基础上,至少约75mcg/升叶黄素,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1∶2至约10∶1和配方产品没有卵磷脂类。
2.权利要求1的婴儿配方产品,其中配方产品包含约75至约230mcg/升的所加叶黄素。
3.权利要求1的婴儿配方产品,其中配方产品包含约100至约200mcg/升叶黄素。
4.权利要求1的婴儿配方产品,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1.5∶1至约10∶1。
5.权利要求1的婴儿配方产品,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约2∶1至约5∶1。
6.权利要求1的婴儿配方产品,其中配方产品具有热量密度20至30kcal/流体盎司。
7.权利要求1的婴儿配方产品,其中配方产品包含游离叶黄素和来自单一源的玉米黄素的组合,所述来源是万寿菊的纯化结晶提取物,其中游离叶黄素占该组合的85%至95%重量和游离玉米黄素占该组合的约5%至约15%重量。
8.权利要求1的婴儿配方产品,其中配方产品是粉末。
9.权利要求1的婴儿配方产品,其中配方产品是液体。
10.权利要求1的婴儿配方产品,其中叶黄素包含至少25%重量的所加叶黄素。
11.一种婴儿配方产品,包含,在待喂基础上,
(a)约54至约108gm/升碳水化合物,
(b)约20至约54gm/升脂肪,
(c)约7至约24gm/升蛋白质,
(d)约100至约200mcg/升叶黄素,和
(e)二十二碳六烯酸,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约2∶1至约5∶1和配方产品没有卵磷脂类。
12.权利要求11的婴儿配方产品,其中配方产品包含游离叶黄素和来自单一源的玉米黄素的组合,所述来源是万寿菊的纯化结晶提取物,其中游离叶黄素占该组合的85%至95%重量和游离玉米黄素占该组合的约5%至约15%重量。
13.根据权利要求1的配方产品在制备用于减少需要的早产婴儿的早熟性视网膜病的危险的产品中用途,其中所述产品提供婴儿约7至约300mcg/kg/天的叶黄素。
14.根据权利要求1的配方产品在制备用于减少需要的早产婴儿的早熟性视网膜病的危险的产品中用途,其中所述产品提供婴儿约14至约220mcg/kg/天的叶黄素。
15.根据权利要求1的配方产品在制备用于促进需要的婴儿的视网膜健康和视觉发育的产品中用途,其中所述产品提供婴儿约7至约300mcg/kg/天的叶黄素。
16.根据权利要求1的配方产品在制备用于促进需要的婴儿的视网膜健康和视觉发育的产品中用途,其中所述产品提供婴儿约14至约220mcg/kg/天的叶黄素。
17.一种婴儿配方产品,包含脂肪,蛋白质,碳水化合物,维生素,和矿物,包括二十二碳六烯酸和,在待喂基础上,约75mcg/升叶黄素至约1150mcg/升叶黄素,其中叶黄素(mcg)与二十二碳六烯酸(mg)的重量比是约1∶2至约10∶1和配方产品没有卵磷脂类。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310096170.XA CN103211225B (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73028305P | 2005-10-26 | 2005-10-26 | |
US60/730,283 | 2005-10-26 | ||
PCT/US2006/041303 WO2007050521A2 (en) | 2005-10-26 | 2006-10-23 | Infant formulas containing docosahexaenoic acid and lutein |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310096205XA Division CN103169093A (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
CN201310096170.XA Division CN103211225B (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101299933A CN101299933A (zh) | 2008-11-05 |
CN101299933B true CN101299933B (zh) | 2013-04-24 |
Family
ID=37771124
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310096170.XA Active CN103211225B (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
CN2006800396657A Active CN101299933B (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
CN201310096205XA Pending CN103169093A (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310096170.XA Active CN103211225B (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310096205XA Pending CN103169093A (zh) | 2005-10-26 | 2006-10-23 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
Country Status (23)
Country | Link |
---|---|
US (1) | US7829126B2 (zh) |
EP (2) | EP1945045B1 (zh) |
JP (2) | JP5473330B2 (zh) |
KR (2) | KR101106944B1 (zh) |
CN (3) | CN103211225B (zh) |
AU (1) | AU2006306366B2 (zh) |
BR (1) | BRPI0617692A2 (zh) |
CA (2) | CA2625001C (zh) |
CR (1) | CR9888A (zh) |
DK (2) | DK1945045T3 (zh) |
EC (1) | ECSP088389A (zh) |
ES (2) | ES2682074T3 (zh) |
HK (2) | HK1117351A1 (zh) |
HN (1) | HN2008000653A (zh) |
IL (2) | IL190479A (zh) |
MX (1) | MX347958B (zh) |
MY (2) | MY146618A (zh) |
NI (1) | NI200800129A (zh) |
RU (1) | RU2445796C2 (zh) |
SV (1) | SV2008002886A (zh) |
TR (1) | TR201808714T4 (zh) |
WO (1) | WO2007050521A2 (zh) |
ZA (1) | ZA200802949B (zh) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228392A1 (en) * | 2002-06-06 | 2003-12-11 | Wyeth | Infant formula compositions containing lutein and zeaxanthin |
EP1864654A1 (en) * | 2002-06-06 | 2007-12-12 | Wyeth a Corporation of the State of Delaware | Infant formula compositions containing lutein and zeaxanthin |
CA2537452C (en) * | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
PT1888081T (pt) | 2005-05-23 | 2017-03-01 | Massachusetts Inst Technology | Composições contendo pufa e seus métodos de utilização |
US20070166354A1 (en) * | 2005-10-26 | 2007-07-19 | Bridget Barrett-Reis | Method of reducing the risk of retinopathy of prematurity in preterm infants |
US7829126B2 (en) * | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
EP1800675B1 (en) * | 2005-12-23 | 2011-05-18 | N.V. Nutricia | Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia |
US20100048705A1 (en) * | 2006-11-09 | 2010-02-25 | Children's Medical Center Corporation | Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids |
WO2009037562A2 (en) * | 2007-09-19 | 2009-03-26 | Ophthalmopharma Ag | Nutritional supplement formulations and fortified foods comprising such supplements |
WO2009057994A1 (en) * | 2007-11-02 | 2009-05-07 | N.V. Nutricia | Unit dosage for brain health |
US20090118228A1 (en) * | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
AR070405A1 (es) * | 2008-02-04 | 2010-04-07 | Novartis Ag | Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual |
CN101548698B (zh) * | 2008-04-03 | 2012-03-14 | 光明乳业股份有限公司 | 母乳化配方牛奶及其制备方法 |
CN101595977B (zh) † | 2008-06-02 | 2013-04-03 | 浙江医药股份有限公司新昌制药厂 | 有益于眼睛明视持久度的配方食品及其应用 |
JP2010126495A (ja) * | 2008-11-28 | 2010-06-10 | Morinaga Milk Ind Co Ltd | 母乳添加用粉末 |
TW201121431A (en) * | 2009-12-01 | 2011-07-01 | Abbott Lab | Soy protein-based nutritional formula with superior stability |
CA2815812C (en) | 2010-11-02 | 2018-10-23 | Abbott Laboratories | Stable concentrated liquid human milk fortifier |
WO2012091542A1 (en) * | 2010-12-28 | 2012-07-05 | N.V. Nutricia | Combination of components for the prevention and treatment of frailty |
ES2875458T3 (es) | 2010-12-29 | 2021-11-10 | Abbott Lab | Producto nutricional para uso en la reducción de la incidencia de enterocolitis necrosante en un lactante, niño pequeño o niño |
US8703737B2 (en) * | 2010-12-31 | 2014-04-22 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
BR112013016936A2 (pt) | 2010-12-31 | 2019-09-24 | Abbott Lab | métodos de usar oligossacarídeos de leite humano para melhorar a saúde respiratória das vias aéreas |
CN108741083A (zh) | 2010-12-31 | 2018-11-06 | 雅培制药有限公司 | 促进有益细菌生长的中性人乳寡糖 |
MX338174B (es) | 2010-12-31 | 2016-04-06 | Abbott Lab | Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios. |
SG191395A1 (en) | 2010-12-31 | 2013-08-30 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
CA2822222C (en) | 2010-12-31 | 2019-05-07 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
MX2013007692A (es) | 2010-12-31 | 2013-08-15 | Abbott Lab | Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana. |
US20120269929A1 (en) * | 2011-04-22 | 2012-10-25 | Hugh Lippman | Fortified Milk-Based Nutritional Compositions |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
ES2657744T3 (es) | 2011-07-22 | 2018-03-06 | Abbott Laboratories | Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal |
MX368124B (es) | 2011-08-29 | 2019-09-19 | Abbott Lab | Oligosacaridos de leche humana para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal. |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
BR112014016135A8 (pt) * | 2011-12-27 | 2017-07-04 | Abbott Lab | uso de uma fórmula para lactentes com caloria reduzida contendo nucleotídeos e/ou carotenóides para reduzir os efeitos adversos à saúde em uma idade mais avançada |
NZ630210A (en) * | 2012-03-14 | 2016-05-27 | Abbott Lab | Nutritional compositions including rrr -alpha tocopherol and polyunsaturated fatty acids |
RU2484828C1 (ru) * | 2012-04-11 | 2013-06-20 | Анна Викторовна Филимонова | Витаминно-минеральное средство: порошок для приготовления раствора для внутреннего применения |
TW201440654A (zh) * | 2012-12-18 | 2014-11-01 | Abbott Lab | 含有低致敏蛋白質及葉黃素之液態濃縮人乳強化劑 |
CN102986876B (zh) * | 2012-12-26 | 2014-09-03 | 光明乳业股份有限公司 | 一种儿童营养奶昔粉 |
CN105188409A (zh) | 2013-03-13 | 2015-12-23 | 雅培制药有限公司 | 含有RRRα-生育酚的婴儿营养产品 |
US9980939B2 (en) | 2013-03-13 | 2018-05-29 | Abbott Laboratories | Composition for enhancing newborn infant cognitive, brain and/or CNS development and method of using same |
SG11201507219WA (en) * | 2013-03-13 | 2015-10-29 | Abbott Lab | Prenatal and lactation supplements to enhance central nervous system development of offspring |
WO2014165008A1 (en) * | 2013-03-13 | 2014-10-09 | Abbott Laboratories | Method of enhancing bioavailability of dha and other lipid-soluble nutrients |
BR112015024434B1 (pt) * | 2013-03-28 | 2021-07-13 | Dsm Ip Assets B.V. | Composição em pó, processo de produção de uma pré-mistura seca e/ou uma formulação de alimentos secos para crianças e pré-mistura seca e/ou uma formulação de alimentos secos para crianças |
JP6375296B2 (ja) * | 2013-07-10 | 2018-08-15 | ライオン株式会社 | 脳機能改善用内服組成物、脳内アミロイドβ蓄積抑制用内服組成物、脳機能改善用食品組成物及び脳内アミロイドβ蓄積抑制用食品組成物 |
TWI729969B (zh) * | 2013-08-29 | 2021-06-11 | 美商亞培公司 | 具有改良溶解度及生物可利用性之含有親脂性化合物之營養組合物 |
WO2015073515A1 (en) | 2013-11-12 | 2015-05-21 | Abbott Laboratories | Uses of nutritional compositions including natural vitamin e, and polyunsaturated fatty acid |
WO2015187795A1 (en) * | 2014-06-03 | 2015-12-10 | Abbott Laboratories | Nutritional compositions comprising a lipophilic active ingredient |
US9993457B2 (en) * | 2014-11-25 | 2018-06-12 | Abbott Laboratories | Method of improving visual processing, visual acuity, or both by administering compositions comprising RRR-alpha-tocopherol and carotenoid to infants |
WO2016086157A1 (en) * | 2014-11-26 | 2016-06-02 | Abbott Laboratories | Infant formula comprising human milk oligosaccharides, polyunsaturated fatty acids, nucleotides, and lutein |
JP6071988B2 (ja) * | 2014-12-09 | 2017-02-01 | 国立大学法人北海道大学 | 身体活動促進剤 |
JP6646368B2 (ja) * | 2015-06-25 | 2020-02-14 | 株式会社東洋新薬 | 網膜保護組成物 |
ES2795836T3 (es) | 2015-07-29 | 2020-11-24 | Abbott Lab | Productos nutricionales con biodisponibilidad y solubilidad lipófila mejoradas en una forma fácil de mezclar |
CN106668835A (zh) * | 2015-11-06 | 2017-05-17 | 北京康爱营养科技股份有限公司 | 一种用于肿瘤治疗的肠内营养剂及其制备方法 |
CN106890312A (zh) * | 2015-12-18 | 2017-06-27 | 北京康爱营养科技股份有限公司 | 一种适用于肝癌患者的肠内营养剂及其制备方法 |
CN105520137B (zh) * | 2015-12-21 | 2018-03-06 | 北京东方红航天生物技术股份有限公司 | 一种具有缓解视疲劳和保护视力功能的保健食品 |
CA3051900A1 (en) * | 2017-05-04 | 2018-11-08 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Neurodevelopment-promoting food compositions and kits, systems and methods related thereto |
US20220039449A1 (en) * | 2018-09-25 | 2022-02-10 | Societe Des Produits Nestle S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
CN109793044A (zh) * | 2019-03-21 | 2019-05-24 | 贝因美(杭州)食品研究院有限公司 | 一种适用于早产/低出生体重婴儿食用的配方奶粉及其制备方法 |
US11849747B1 (en) * | 2019-06-24 | 2023-12-26 | PBM Nutritionals, LLC | Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof |
CN110236189A (zh) * | 2019-06-25 | 2019-09-17 | 海普诺凯营养品有限公司 | 一种保护视力的组合物及其制备方法和应用 |
JP6736137B2 (ja) * | 2019-07-11 | 2020-08-05 | 株式会社東洋新薬 | 網膜保護組成物 |
TR202002876A2 (tr) * | 2020-02-25 | 2021-09-21 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Pedi̇atri̇k sağliğin i̇yi̇leşti̇ri̇lmesi̇ne yöneli̇k besi̇n kompozi̇syonlari |
WO2023041776A1 (en) * | 2021-09-17 | 2023-03-23 | N.V. Nutricia | Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases |
WO2024062125A1 (en) | 2022-09-23 | 2024-03-28 | N.V. Nutricia | A process of preparing an enteral nutritional composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228392A1 (en) * | 2002-06-06 | 2003-12-11 | Wyeth | Infant formula compositions containing lutein and zeaxanthin |
US20050208179A1 (en) * | 2004-03-18 | 2005-09-22 | Albrecht Daniel S | Nutritional formula containing select carotenoid combinations |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0568606T3 (da) * | 1991-01-24 | 2001-07-23 | Martek Corp | Mikrobielle olieblandinger og anvendelser deraf |
US6080787A (en) | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
EP1039892B1 (en) | 1997-02-21 | 2004-04-28 | Abbott Laboratories | Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis |
AU752468B2 (en) * | 1997-04-04 | 2002-09-19 | Phyllis E. Bowen | Lutein esters having high bioavailability |
US6365218B1 (en) | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6495599B2 (en) | 2000-04-13 | 2002-12-17 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses therof |
DE10030781A1 (de) | 2000-06-29 | 2002-01-17 | Hassan Jomaa | Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen |
US7090862B2 (en) * | 2001-03-30 | 2006-08-15 | Abbott Laboratories | Method of improving the antioxidant status of an infant |
JP2003026589A (ja) * | 2001-07-16 | 2003-01-29 | Naturally Plus:Kk | 眼病予防および視覚改善剤 |
US6811801B2 (en) | 2001-12-12 | 2004-11-02 | Abbott Laboratories | Methods and compositions for brightening the color of thermally processed nutritionals |
US6913778B2 (en) * | 2001-12-21 | 2005-07-05 | Wyeth | Infant formula compositions comprising increased amounts of alpha-lactalbumin |
US20040076691A1 (en) | 2002-01-16 | 2004-04-22 | David Haines | Anti-inflammatory formulations |
AR039170A1 (es) * | 2002-03-28 | 2005-02-09 | Bio Dar Ltd | Co-granulos de dha y romero y metodos de uso |
US6649195B1 (en) * | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
CN1481829A (zh) * | 2002-09-09 | 2004-03-17 | 高宾生 | 万寿菊花粉保健食品 |
US7867541B2 (en) * | 2003-04-14 | 2011-01-11 | Mead Johnson Nutrition Company | Compositions and methods of formulation for enteral formulas containing sialic acid |
JP2005065525A (ja) * | 2003-08-20 | 2005-03-17 | Koyo Shokai:Kk | ルテインおよびブルーベリー含有飲料 |
RU2321582C2 (ru) * | 2004-01-16 | 2008-04-10 | Индэс Байотек Прайвет Лимитед | Способ получения стабильной лютеиновой пасты из эфирного масла |
US20070082044A1 (en) | 2004-03-10 | 2007-04-12 | Trustees Of Tufts College | Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene |
WO2005110375A1 (en) | 2004-05-08 | 2005-11-24 | Paul Edward L Jr | Nutritional supplement for treatment of ocular diseases |
US20060088574A1 (en) * | 2004-10-25 | 2006-04-27 | Manning Paul B | Nutritional supplements |
FR2882894B1 (fr) | 2005-03-11 | 2009-04-03 | Larena Sa | Composition alimentaire suppletive |
US20060270739A1 (en) * | 2005-04-28 | 2006-11-30 | Trustees Of Tufts College | Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation |
WO2006116755A2 (en) | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
US7829126B2 (en) * | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
-
2006
- 2006-10-20 US US11/584,704 patent/US7829126B2/en active Active
- 2006-10-23 ES ES10189228.9T patent/ES2682074T3/es active Active
- 2006-10-23 MX MX2012003044A patent/MX347958B/es unknown
- 2006-10-23 AU AU2006306366A patent/AU2006306366B2/en active Active
- 2006-10-23 RU RU2008120696/13A patent/RU2445796C2/ru active
- 2006-10-23 CA CA2625001A patent/CA2625001C/en active Active
- 2006-10-23 DK DK06826479.5T patent/DK1945045T3/en active
- 2006-10-23 CA CA2747281A patent/CA2747281A1/en not_active Withdrawn
- 2006-10-23 TR TR2018/08714T patent/TR201808714T4/tr unknown
- 2006-10-23 WO PCT/US2006/041303 patent/WO2007050521A2/en active Application Filing
- 2006-10-23 CN CN201310096170.XA patent/CN103211225B/zh active Active
- 2006-10-23 KR KR1020087010061A patent/KR101106944B1/ko active IP Right Grant
- 2006-10-23 CN CN2006800396657A patent/CN101299933B/zh active Active
- 2006-10-23 JP JP2008537844A patent/JP5473330B2/ja active Active
- 2006-10-23 ES ES06826479.5T patent/ES2552674T3/es active Active
- 2006-10-23 BR BRPI0617692-5A patent/BRPI0617692A2/pt not_active Application Discontinuation
- 2006-10-23 MY MYPI20081000A patent/MY146618A/en unknown
- 2006-10-23 EP EP06826479.5A patent/EP1945045B1/en not_active Revoked
- 2006-10-23 EP EP10189228.9A patent/EP2283736B1/en not_active Revoked
- 2006-10-23 DK DK10189228.9T patent/DK2283736T3/en active
- 2006-10-23 KR KR1020117021428A patent/KR101302629B1/ko active IP Right Grant
- 2006-10-23 CN CN201310096205XA patent/CN103169093A/zh active Pending
- 2006-10-26 MY MYPI2011004051A patent/MY158307A/en unknown
-
2008
- 2008-03-27 IL IL190479A patent/IL190479A/en active IP Right Grant
- 2008-04-03 ZA ZA200802949A patent/ZA200802949B/xx unknown
- 2008-04-15 CR CR9888A patent/CR9888A/es unknown
- 2008-04-21 EC EC2008008389A patent/ECSP088389A/es unknown
- 2008-04-25 SV SV2008002886A patent/SV2008002886A/es not_active Application Discontinuation
- 2008-04-25 NI NI200800129A patent/NI200800129A/es unknown
- 2008-04-28 HN HN2008000653A patent/HN2008000653A/es unknown
- 2008-11-10 HK HK08112312.8A patent/HK1117351A1/zh unknown
-
2012
- 2012-01-19 IL IL217636A patent/IL217636A/en active IP Right Grant
- 2012-02-06 JP JP2012022860A patent/JP5572645B2/ja active Active
-
2014
- 2014-01-21 HK HK14100627.5A patent/HK1187499A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228392A1 (en) * | 2002-06-06 | 2003-12-11 | Wyeth | Infant formula compositions containing lutein and zeaxanthin |
US20050208179A1 (en) * | 2004-03-18 | 2005-09-22 | Albrecht Daniel S | Nutritional formula containing select carotenoid combinations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101299933B (zh) | 包含二十二碳六烯酸和叶黄素的婴儿配方 | |
US10342244B2 (en) | Infant formulas containing docosahexaenoic acid and lutein | |
CA2498973C (en) | Nutritional formula containing select carotenoid combinations | |
IE55320B1 (en) | Infant foods | |
CN104427887A (zh) | 包含RRR-α生育酚和多不饱和脂肪酸的营养组合物 | |
AU2003251396B2 (en) | Infant formula compositions containing lutein and zeaxanthin | |
CN105828816A (zh) | 包含天然维生素e和多不饱和脂肪酸的营养组合物的用途 | |
AU2011218634B2 (en) | Infant formulas containing docosahexaenoic acid and lutein | |
RU2587862C2 (ru) | Смесь для детского питания (варианты), способ уменьшения риска развития ретролентальной фиброплазии (варианты) и способ укрепления здорового состояния сетчатки и развития зрения (варианты) при ее использовании | |
Derevitskay et al. | Meat-based enteral nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |